CytomX Therapeutics Inc. (NASDAQ:CTMX) is one of the best growth stocks under $30 to buy now. On June 3, CytomX expanded its ...
Sean A. McCarthy, the CEO of $CTMX, sold 37,656 shares of the company on 03-18-2025 for an estimated $22,555. We received data on the trade from a recent SEC filing ...
CytomX Therapeutics (NASDAQ:CTMX) stock is falling hard on Tuesday after the clinical-stage, oncology-focused biopharmaceutical company released its latest earnings report. The CytomX Therapeutics ...
CytomX Therapeutics (CTMX Quick Quote CTMX - Free Report) has been beaten down lately with too much selling pressure. While the stock has lost 25.6% over the past four weeks, there is light at the end ...
Christopher Ogden, the Chief Financial Officer of $CTMX, sold 10,614 shares of the company on 06-16-2025 for an estimated $28,539. We received data on the trade from ...
CytomX provide an initial CX-904 Phase 1a dose escalation update on May 8 after the close of markets. CytomX and Amgen are developing CX-904, a T-cell-engaging bispecific Probody candidate against the ...
The price trend for CytomX Therapeutics (CTMX Quick Quote CTMX - Free Report) has been bearish lately and the stock has lost 5.9% over the past week. However, the formation of a hammer chart pattern ...
CytomX Therapeutics presents a trade opportunity centered on upcoming Q1'26 clinical data for its masked, EpCAM-targeting, antibody-drug conjugate. Previous phase 1 data showed a compelling response ...
Shares of CytomX TherapeuticsCTMX soared 44.2% on Monday after the company reported positive phase I expansion data for its EpCAM-targeting PROBODY ADC, varsetatug masetecan (Varseta-M), in late-line ...
The latest price target for CytomX Therapeutics (NASDAQ:CTMX) was reported by HC Wainwright & Co. on November 11, 2025. The analyst firm set a price target for $10.00 expecting CTMX to rise to within ...
CytomX Therapeutics (NASDAQ:CTMX) stock is taking a beating on Thursday following a clinical trial update from the oncology-focused biopharmaceutical company. CytomX Therapeutics’ latest clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results